Global Uterine Sarcoma Market

Uterine Sarcoma Comprehensive Study by Type (Uterine leiomyosarcoma (LMS), Endometrial stromal sarcoma (ESS), Undifferentiated sarcoma), Diagnosis (Surgery, Radiotherapy, Chemotherapy, Hormone therapy), End User (Hospital, Clinics), Stages (Stage I(IA, IB), Stage II(IIA ,IIB), Stage lll(lllA, lllB, lllC), Stage lV (lVA, lVB)) Players and Region - Global Market Outlook to 2030

Uterine Sarcoma Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Sarcomas are the tumours of the mesenchymal tissues like bone muscle connective tissue ligament and fat. Uterine sarcoma is a rare type of cancer that starts in the muscle and supporting tissues of the uterus, Uterine sarcoma arise from dividing cell populations between the myometrium or connective tissue elements within the endometrium. Exposure to X-rays increases the risk of uterine sarcoma. Unusual vaginal bleeding spotting or discharge are some of the common symptoms of the disease. The increasing prevalence of uterine sarcoma and the growing female geriatric population are the major drivers for the market growth Datamonitor Healthcare estimates that in 2019 there were 385200 incident cases of uterine cancer in females worldwide and expects that number to increase to 404300 incident cases by 2028, it is also estimated 1.3 million five-year prevalent cases of uterine cancer worldwide which is expected to increase slightly to 1.4 million cases by 2028. The increasing number of different types of cancer cases among women one of the key driving factor of the growth.

Highlights from Uterine Sarcoma Market Study
AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The key Players profiled in the report are Pfizer Inc. (United States), Intas Pharmaceuticals Ltd. (India), FMC Corporation (United States), Sun Pharmaceutical Industries Ltd. (India), Johnson & Johnson Services Inc. (United States), General Electric Company (United States), Koninklijke Philips N.V. (Netherlands) and Siemens Healthcare Private Limited (Germany). Additionally, other players that are part of this comprehensive study are Millennium Pharmaceuticals, Inc. (United States), BeiGene, Ltd. (China), Kyowa Kirin Co., Ltd. (Japan), Oncobiologics Inc. (United States) and Takeda Pharmaceutical Company Limited (Japan).

Geographic Breakdown and Segment Analysis
The Global Uterine Sarcoma market presents a comprehensive analysis of the Uterine Sarcoma market by product type (Uterine leiomyosarcoma (LMS), Endometrial stromal sarcoma (ESS) and Undifferentiated sarcoma), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Uterine Sarcoma industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the holds majority of market share of the Uterine Sarcoma market

Analyst at AMA have segmented the market study of Global Uterine Sarcoma market by Type, Application and Region.

Influencing Trend:
Increasing Healthcare Expenditure and Chemotherapy is trending and to hold the Highest shares

Market Growth Drivers:
Rising Awareness about Uterine Diseases and their Available Therapies and Increasing awareness for women health and the growing healthcare sector are the major drivers for the market growth within the region

Challenges:
Adverse effects of the treatment and high toxicity of drugs

Restraints:
High Cost Associated with the Treatment

Opportunities:
Innovation in Drug Development and Subsequent Technological Advancements

Market Developments Activities:
In June 2023, The National Cancer Institute collaborates with pharmaceutical companies on clinical trials for targeted therapies and immunotherapy combinations for specific uterine sarcoma subtypes.
In October 2023, Researchers at MD Anderson Cancer Center announce the development of a novel blood test for early detection of uterine sarcoma, potentially leading to earlier diagnoses and improved patient outcomes.



The companies are exploring the market by adopting mergers & acquisitions expansions investments new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Key Target Audience
Pharmaceutical companies, Biotechnological institutes, Research and Development (R&D) Companies, Medical Research Laboratories and Market Research and Consulting Service Providers

Report Objectives / Segmentation Covered

By Type
  • Uterine leiomyosarcoma (LMS)
  • Endometrial stromal sarcoma (ESS)
  • Undifferentiated sarcoma
By Diagnosis
  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Hormone therapy

By End User
  • Hospital
  • Clinics

By Stages
  • Stage I(IA, IB)
  • Stage II(IIA ,IIB)
  • Stage lll(lllA, lllB, lllC)
  • Stage lV (lVA, lVB)

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness about Uterine Diseases and their Available Therapies
      • 3.2.2. Increasing awareness for women health and the growing healthcare sector are the major drivers for the market growth within the region
    • 3.3. Market Challenges
      • 3.3.1. Adverse effects of the treatment and high toxicity of drugs
    • 3.4. Market Trends
      • 3.4.1. Increasing Healthcare Expenditure
      • 3.4.2. Chemotherapy is trending and to hold the Highest shares
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Uterine Sarcoma, by Type, Diagnosis , End User , Stages and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Uterine Sarcoma (Value)
      • 5.2.1. Global Uterine Sarcoma by: Type (Value)
        • 5.2.1.1. Uterine leiomyosarcoma (LMS)
        • 5.2.1.2. Endometrial stromal sarcoma (ESS)
        • 5.2.1.3. Undifferentiated sarcoma
      • 5.2.2. Global Uterine Sarcoma Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
    • 5.3. Global Uterine Sarcoma (Price)
      • 5.3.1. Global Uterine Sarcoma by: Type (Price)
  • 6. Uterine Sarcoma: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Intas Pharmaceuticals Ltd. (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. FMC Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Johnson & Johnson Services Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. General Electric Company (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Koninklijke Philips N.V. (Netherlands)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Siemens Healthcare Private Limited (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Uterine Sarcoma Sale, by Type, Diagnosis , End User , Stages and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Uterine Sarcoma (Value)
      • 7.2.1. Global Uterine Sarcoma by: Type (Value)
        • 7.2.1.1. Uterine leiomyosarcoma (LMS)
        • 7.2.1.2. Endometrial stromal sarcoma (ESS)
        • 7.2.1.3. Undifferentiated sarcoma
      • 7.2.2. Global Uterine Sarcoma Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
    • 7.3. Global Uterine Sarcoma (Price)
      • 7.3.1. Global Uterine Sarcoma by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Uterine Sarcoma: by Type(USD Million)
  • Table 2. Uterine Sarcoma Uterine leiomyosarcoma (LMS) , by Region USD Million (2018-2023)
  • Table 3. Uterine Sarcoma Endometrial stromal sarcoma (ESS) , by Region USD Million (2018-2023)
  • Table 4. Uterine Sarcoma Undifferentiated sarcoma , by Region USD Million (2018-2023)
  • Table 5. South America Uterine Sarcoma, by Country USD Million (2018-2023)
  • Table 6. South America Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 7. South America Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 8. South America Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 9. South America Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 10. Brazil Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 11. Brazil Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 12. Brazil Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 13. Brazil Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 14. Argentina Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 15. Argentina Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 16. Argentina Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 17. Argentina Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 18. Rest of South America Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 19. Rest of South America Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 20. Rest of South America Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 21. Rest of South America Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 22. Asia Pacific Uterine Sarcoma, by Country USD Million (2018-2023)
  • Table 23. Asia Pacific Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 24. Asia Pacific Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 25. Asia Pacific Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 26. Asia Pacific Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 27. China Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 28. China Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 29. China Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 30. China Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 31. Japan Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 32. Japan Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 33. Japan Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 34. Japan Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 35. India Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 36. India Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 37. India Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 38. India Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 39. South Korea Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 40. South Korea Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 41. South Korea Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 42. South Korea Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 43. Taiwan Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 44. Taiwan Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 45. Taiwan Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 46. Taiwan Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 47. Australia Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 48. Australia Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 49. Australia Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 50. Australia Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 55. Europe Uterine Sarcoma, by Country USD Million (2018-2023)
  • Table 56. Europe Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 57. Europe Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 58. Europe Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 59. Europe Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 60. Germany Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 61. Germany Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 62. Germany Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 63. Germany Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 64. France Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 65. France Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 66. France Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 67. France Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 68. Italy Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 69. Italy Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 70. Italy Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 71. Italy Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 72. United Kingdom Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 73. United Kingdom Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 74. United Kingdom Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 75. United Kingdom Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 76. Netherlands Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 77. Netherlands Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 78. Netherlands Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 79. Netherlands Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 80. Rest of Europe Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 81. Rest of Europe Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 82. Rest of Europe Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 83. Rest of Europe Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 84. MEA Uterine Sarcoma, by Country USD Million (2018-2023)
  • Table 85. MEA Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 86. MEA Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 87. MEA Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 88. MEA Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 89. Middle East Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 90. Middle East Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 91. Middle East Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 92. Middle East Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 93. Africa Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 94. Africa Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 95. Africa Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 96. Africa Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 97. North America Uterine Sarcoma, by Country USD Million (2018-2023)
  • Table 98. North America Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 99. North America Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 100. North America Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 101. North America Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 102. United States Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 103. United States Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 104. United States Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 105. United States Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 106. Canada Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 107. Canada Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 108. Canada Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 109. Canada Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 110. Mexico Uterine Sarcoma, by Type USD Million (2018-2023)
  • Table 111. Mexico Uterine Sarcoma, by Diagnosis USD Million (2018-2023)
  • Table 112. Mexico Uterine Sarcoma, by End User USD Million (2018-2023)
  • Table 113. Mexico Uterine Sarcoma, by Stages USD Million (2018-2023)
  • Table 114. Uterine Sarcoma: by Type(USD/Units)
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Company Basic Information, Sales Area and Its Competitors
  • Table 118. Company Basic Information, Sales Area and Its Competitors
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Uterine Sarcoma: by Type(USD Million)
  • Table 124. Uterine Sarcoma Uterine leiomyosarcoma (LMS) , by Region USD Million (2025-2030)
  • Table 125. Uterine Sarcoma Endometrial stromal sarcoma (ESS) , by Region USD Million (2025-2030)
  • Table 126. Uterine Sarcoma Undifferentiated sarcoma , by Region USD Million (2025-2030)
  • Table 127. South America Uterine Sarcoma, by Country USD Million (2025-2030)
  • Table 128. South America Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 129. South America Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 130. South America Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 131. South America Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 132. Brazil Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 133. Brazil Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 134. Brazil Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 135. Brazil Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 136. Argentina Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 137. Argentina Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 138. Argentina Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 139. Argentina Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 140. Rest of South America Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 141. Rest of South America Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 142. Rest of South America Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 143. Rest of South America Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 144. Asia Pacific Uterine Sarcoma, by Country USD Million (2025-2030)
  • Table 145. Asia Pacific Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 146. Asia Pacific Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 147. Asia Pacific Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 148. Asia Pacific Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 149. China Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 150. China Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 151. China Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 152. China Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 153. Japan Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 154. Japan Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 155. Japan Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 156. Japan Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 157. India Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 158. India Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 159. India Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 160. India Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 161. South Korea Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 162. South Korea Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 163. South Korea Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 164. South Korea Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 165. Taiwan Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 166. Taiwan Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 167. Taiwan Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 168. Taiwan Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 169. Australia Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 170. Australia Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 171. Australia Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 172. Australia Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 173. Rest of Asia-Pacific Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 174. Rest of Asia-Pacific Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 175. Rest of Asia-Pacific Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 176. Rest of Asia-Pacific Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 177. Europe Uterine Sarcoma, by Country USD Million (2025-2030)
  • Table 178. Europe Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 179. Europe Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 180. Europe Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 181. Europe Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 182. Germany Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 183. Germany Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 184. Germany Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 185. Germany Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 186. France Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 187. France Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 188. France Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 189. France Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 190. Italy Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 191. Italy Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 192. Italy Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 193. Italy Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 194. United Kingdom Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 195. United Kingdom Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 196. United Kingdom Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 197. United Kingdom Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 198. Netherlands Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 199. Netherlands Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 200. Netherlands Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 201. Netherlands Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 202. Rest of Europe Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 203. Rest of Europe Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 204. Rest of Europe Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 205. Rest of Europe Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 206. MEA Uterine Sarcoma, by Country USD Million (2025-2030)
  • Table 207. MEA Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 208. MEA Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 209. MEA Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 210. MEA Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 211. Middle East Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 212. Middle East Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 213. Middle East Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 214. Middle East Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 215. Africa Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 216. Africa Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 217. Africa Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 218. Africa Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 219. North America Uterine Sarcoma, by Country USD Million (2025-2030)
  • Table 220. North America Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 221. North America Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 222. North America Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 223. North America Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 224. United States Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 225. United States Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 226. United States Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 227. United States Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 228. Canada Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 229. Canada Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 230. Canada Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 231. Canada Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 232. Mexico Uterine Sarcoma, by Type USD Million (2025-2030)
  • Table 233. Mexico Uterine Sarcoma, by Diagnosis USD Million (2025-2030)
  • Table 234. Mexico Uterine Sarcoma, by End User USD Million (2025-2030)
  • Table 235. Mexico Uterine Sarcoma, by Stages USD Million (2025-2030)
  • Table 236. Uterine Sarcoma: by Type(USD/Units)
  • Table 237. Research Programs/Design for This Report
  • Table 238. Key Data Information from Secondary Sources
  • Table 239. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Uterine Sarcoma: by Type USD Million (2018-2023)
  • Figure 5. South America Uterine Sarcoma Share (%), by Country
  • Figure 6. Asia Pacific Uterine Sarcoma Share (%), by Country
  • Figure 7. Europe Uterine Sarcoma Share (%), by Country
  • Figure 8. MEA Uterine Sarcoma Share (%), by Country
  • Figure 9. North America Uterine Sarcoma Share (%), by Country
  • Figure 10. Global Uterine Sarcoma: by Type USD/Units (2018-2023)
  • Figure 11. Global Uterine Sarcoma share by Players 2023 (%)
  • Figure 12. Global Uterine Sarcoma share by Players (Top 3) 2023(%)
  • Figure 13. Global Uterine Sarcoma share by Players (Top 5) 2023(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 17. Intas Pharmaceuticals Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 18. Intas Pharmaceuticals Ltd. (India) Revenue: by Geography 2023
  • Figure 19. FMC Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 20. FMC Corporation (United States) Revenue: by Geography 2023
  • Figure 21. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 22. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2023
  • Figure 23. Johnson & Johnson Services Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Johnson & Johnson Services Inc. (United States) Revenue: by Geography 2023
  • Figure 25. General Electric Company (United States) Revenue, Net Income and Gross profit
  • Figure 26. General Electric Company (United States) Revenue: by Geography 2023
  • Figure 27. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 28. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2023
  • Figure 29. Siemens Healthcare Private Limited (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Siemens Healthcare Private Limited (Germany) Revenue: by Geography 2023
  • Figure 31. Global Uterine Sarcoma: by Type USD Million (2025-2030)
  • Figure 32. South America Uterine Sarcoma Share (%), by Country
  • Figure 33. Asia Pacific Uterine Sarcoma Share (%), by Country
  • Figure 34. Europe Uterine Sarcoma Share (%), by Country
  • Figure 35. MEA Uterine Sarcoma Share (%), by Country
  • Figure 36. North America Uterine Sarcoma Share (%), by Country
  • Figure 37. Global Uterine Sarcoma: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Intas Pharmaceuticals Ltd. (India)
  • FMC Corporation (United States)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Johnson & Johnson Services Inc. (United States)
  • General Electric Company (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • Siemens Healthcare Private Limited (Germany)
Additional players considered in the study are as follows:
Millennium Pharmaceuticals, Inc. (United States) , BeiGene, Ltd. (China) , Kyowa Kirin Co., Ltd. (Japan) , Oncobiologics Inc. (United States) , Takeda Pharmaceutical Company Limited (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 224 Pages 64 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Uterine Sarcoma Market Quantitative research analysis
Global Uterine Sarcoma Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2030
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Adverse effects of the treatment and high toxicity of drugs

Know More About Global Uterine Sarcoma Market Report?

Have a Query? Click Here

Other Related Reports

Serotonin Syndrome Treatment Comprehensive Study by Type (Medication, Hospitalization), Application (Influencing learning,, Memory,, Happiness as well as regulating body temperature, Sleep,, Sexual b...
$ 3650
Radiation Toxicity Treatment Comprehensive Study by Type (Potassium Iodide (ThyroShield, Iosat), Prussian blue (Radiogardase), Diethylenetriamine pentaacetic acid (DTPA), Others), Application (Hospit...
$ 3750
Swollen Knee Comprehensive Study by Type (Acute Knee Swelling, Chronic Knee Swelling), Treatment (Medications, Surgical Procedures (Arthrocentesis, Arthroscopy and Joint replacement)), End-user (Hosp...
$ 3450
Diabetic Macular Edema Treatment Comprehensive Study by Type (Laser Photocoagulation Therapy, Pharmacological Therapy, Bevacizumab, Ranibizumab, Triamcinolone), Indication (Diffuse Diabetic Macular E...
$ 3750
Propionic Acidemia Comprehensive Study by Type (Neonatal-Onset PA, Late-Onset PA), Application (Hospitals & Clinics, Medicinal & Pharmaceutical Stores), Treatment Type (Carnitine Supplementation, Flu...
$ 3450
Ataxia-Telangiectasia Comprehensive Study by Distribution Channel (Hospital Pharmacies, Online Pharmacies), Diagnosis Type (IgA and Serum Alpha-1 Fetoprotein Levels, Genetic Testing), Treatment Type ...
$ 3350